These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35965582)

  • 21. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
    Krösser S; Neugebauer R; Dolgos H; Fluck M; Rost KL; Kovar A
    Eur J Clin Pharmacol; 2006 Apr; 62(4):277-84. PubMed ID: 16525816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sex differences in pharmacokinetics and pharmacodynamics.
    Gandhi M; Aweeka F; Greenblatt RM; Blaschke TF
    Annu Rev Pharmacol Toxicol; 2004; 44():499-523. PubMed ID: 14744256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
    van Schaik RH
    Invest New Drugs; 2005 Dec; 23(6):513-22. PubMed ID: 16267627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance.
    Yang Y; Liu X
    Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32290519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs.
    Philip PA; Ali-Sadat S; Doehmer J; Kocarek T; Akhtar A; Lu H; Chan KK
    Cancer Chemother Pharmacol; 1999; 43(1):59-67. PubMed ID: 9923542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacology, Part 2: Introduction to Pharmacokinetics.
    Currie GM
    J Nucl Med Technol; 2018 Sep; 46(3):221-230. PubMed ID: 29724803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug interactions of macrolides: emphasis on dirithromycin.
    Watkins VS; Polk RE; Stotka JL
    Ann Pharmacother; 1997 Mar; 31(3):349-56. PubMed ID: 9066944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioanalytical methods for the determination of itraconazole and hydroxyitraconazole: overview from clinical pharmacology, pharmacokinetic, pharmacodynamic and metabolism perspectives.
    Yao M; Srinivas NR
    Biomed Chromatogr; 2009 Jul; 23(7):677-91. PubMed ID: 19309762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.
    Zhou-Pan XR; Sérée E; Zhou XJ; Placidi M; Maurel P; Barra Y; Rahmani R
    Cancer Res; 1993 Nov; 53(21):5121-6. PubMed ID: 8221648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics/Pharmacodynamics of Antiarrhythmic Drugs.
    Indik JH; Woosley RL
    Card Electrophysiol Clin; 2010 Sep; 2(3):341-358. PubMed ID: 28770794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of cytochrome P450 activity: implications for cancer therapy.
    Scripture CD; Sparreboom A; Figg WD
    Lancet Oncol; 2005 Oct; 6(10):780-9. PubMed ID: 16198984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.
    Tracy TS; Chaudhry AS; Prasad B; Thummel KE; Schuetz EG; Zhong XB; Tien YC; Jeong H; Pan X; Shireman LM; Tay-Sontheimer J; Lin YS
    Drug Metab Dispos; 2016 Mar; 44(3):343-51. PubMed ID: 26681736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Basic pharmacology and pharmacokinetics.
    Rasymas A
    Clin Podiatr Med Surg; 1992 Apr; 9(2):211-21. PubMed ID: 1586899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Drugs on oxygen": an update and perspective on the role of cytochrome P450 testing in pharmacology.
    Tralau T; Luch A
    Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1357-62. PubMed ID: 22970688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of diet on the clinical pharmacology of oral antineoplastic agents.
    Ruggiero A; Cefalo MG; Coccia P; Mastrangelo S; Maurizi P; Riccardi R
    Eur J Clin Pharmacol; 2012 Feb; 68(2):115-22. PubMed ID: 21796375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gender effects in pharmacokinetics and pharmacodynamics.
    Harris RZ; Benet LZ; Schwartz JB
    Drugs; 1995 Aug; 50(2):222-39. PubMed ID: 8521756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan.
    Luong TT; McAnulty MJ; Evers DL; Reinhardt BJ; Weina PJ
    Curr Res Toxicol; 2021; 2():217-224. PubMed ID: 34345864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basic obstetric pharmacology.
    Zhao Y; Hebert MF; Venkataramanan R
    Semin Perinatol; 2014 Dec; 38(8):475-86. PubMed ID: 25281357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
    Brosen K
    Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic drug interactions of macrolides.
    Periti P; Mazzei T; Mini E; Novelli A
    Clin Pharmacokinet; 1992 Aug; 23(2):106-31. PubMed ID: 1511528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.